Literature DB >> 11337299

Results of a screening program for prostate cancer in patients scheduled for abdominoperineal resection for colorectal pathologic findings.

M K Terris1, S M Wren.   

Abstract

OBJECTIVES: Because of the difficulty of accessing the prostate for tissue sampling after surgical removal of the rectum and obliteration of the anus, we started an early detection program for prostate cancer in all men scheduled for abdominoperineal resection.
METHODS: Twenty consecutive men were screened for prostatic adenocarcinoma before planned abdominoperineal resection for colorectal pathologic findings. Patients were 48 to 77 years old (mean 66.9). Screening included serum prostate-specific antigen determination and digital rectal examination. Those patients with suspicious findings underwent transrectal ultrasound-guided sextant biopsies of the prostate.
RESULTS: One patient was excluded because of a prior history of prostate cancer. Six (31.6%) of the remaining 19 patients demonstrated elevated prostate-specific antigen levels (greater than 4.0 ng/mL); two of these patients also had an abnormal digital rectal examination. Transrectal ultrasound and prostate biopsies in these 6 patients revealed prostatic adenocarcinoma in 3 patients (50% of those undergoing biopsies or 15.8% of those screened). The 13 patients who did not undergo prostate biopsies had prostate-specific antigen levels from 0.4 to 2.4 ng/mL (mean 0.9) and normal prostate glands according to the digital rectal examinations.
CONCLUSIONS: Screening for prostate cancer in men 50 years old or older with 10 years or longer life expectancy before they undergo abdominoperineal resection detects a significant number of prostatic malignancies and should be encouraged.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11337299     DOI: 10.1016/s0090-4295(01)00943-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  Management of synchronous rectal and prostate cancer.

Authors:  D O Kavanagh; D M Quinlan; J G Armstrong; J M P Hyland; P R O'Connell; D C Winter
Journal:  Int J Colorectal Dis       Date:  2012-03-28       Impact factor: 2.571

Review 2.  Prostate Cancer Diagnosis, Treatment and Outcomes in Patients with Previous or Synchronous Colorectal Cancer: A Systematic Review of Published Evidence.

Authors:  Giuseppe Celentano; Massimiliano Creta; Luigi Napolitano; Marco Abate; Roberto La Rocca; Marco Capece; Claudia Mirone; Simone Morra; Francesco Di Bello; Luigi Cirillo; Francesco Mangiapia; Gianluigi Califano; Claudia Collà Ruvolo; Caterina Sagnelli; Antonello Sica; Armando Calogero; Fabrizio Iacono; Ferdinando Fusco; Vincenzo Mirone; Nicola Longo
Journal:  Diagnostics (Basel)       Date:  2022-06-15

3.  Prostate carcinomas mimicking a digestive malignancy.

Authors:  Sorin Dema; Alis Liliana Carmen Dema; Sorina Tăban; Bianca Roxana Natarâş; Livius Cosmin Daminescu; Ciprian Constantin Duţă; Alin Adrian Cumpănaş; Tiberiu Răzvan Bardan
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

4.  Metachronous anal canal and prostate cancers with simultaneous definitive therapy: a case report and review of the literature.

Authors:  Edward F Miles; Laura L Jacimore; John W Nelson
Journal:  Case Rep Oncol Med       Date:  2011-09-15

Review 5.  Multidisciplinary approach to synchronous prostate and rectal cancer: current experience and future challenges.

Authors:  Charalampos Seretis; Fotios Seretis; Nikolaos Liakos
Journal:  J Clin Med Res       Date:  2014-03-31

6.  Multi-Institutional Analysis of Synchronous Prostate and Rectosigmoid Cancers.

Authors:  Corbin D Jacobs; Jacob Trotter; Manisha Palta; Michael J Moravan; Yuan Wu; Christopher G Willett; W Robert Lee; Brian G Czito
Journal:  Front Oncol       Date:  2020-03-24       Impact factor: 6.244

7.  Synchronous primary carcinomas of the prostate, thyroid and rectum: case report and review of the literature.

Authors:  Yujiao Long; Weidong Liu; Youyi Dai; Haijun Wu; Xueying Long; Zhan Liang; Rongrong Zhou
Journal:  Transl Cancer Res       Date:  2019-06       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.